Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2012 08:30 ET | Source: Chelsea Therapeutics

Patients With Neurological Diseases Like Parkinson's Disease May Also be Suffering From a Secondary Condition They Didn't Know Existed, New Survey Shows

CHARLOTTE, N.C., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Patients with neurological diseases, such as Parkinson's disease and multiple system atrophy (MSA), may be experiencing symptoms associated with the...
January 26, 2012 08:45 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Joins With Advocates, Patients and Experts to Raise Awareness of Neurogenic Orthostatic Hypotension (NOH)

CHARLOTTE, N.C., Jan. 26, 2012 (GLOBE NEWSWIRE) -- Patients with Parkinson's disease, multiple system atrophy (MSA) and other neurological disorders can be greatly affected by the symptoms of their...
January 11, 2012 09:25 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Exercise of Over-Allotment Option and Completion of the Public Offering of Common Stock

CHARLOTTE, N.C., Jan. 11, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has completed its previously announced underwritten public offering of 4,989,275 shares of...
January 06, 2012 08:45 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Prices Public Offering of Common Stock

CHARLOTTE, N.C., Jan. 6, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that it has priced an underwritten public offering of 4,338,500 shares of its...
January 05, 2012 16:03 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces Proposed Public Offering of Common Stock

CHARLOTTE, N.C., Jan. 5, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today its intention to offer, subject to market and other conditions, $20.0 million...
January 03, 2012 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces FDA Advisory Committee Meeting Date for Review of NORTHERA(TM) NDA for the Treatment of Symptomatic NOH

CHARLOTTE, N.C., Jan. 3, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the...
December 22, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Reports Topline Results From Phase II Trial of Droxidopa in Fibromyalgia

CHARLOTTE, N.C., Dec. 22, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced results of a Phase II dose-finding study designed to evaluate the safety and...
December 15, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Receives Notice of Allowance of Key U.S. Patent for Novel, Controlled Release Formulation of Northera(TM)

CHARLOTTE, N.C., Dec. 15, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) received a notice of allowance from the U.S. Patent & Trademark Office (USPTO) for its...
November 29, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics to Present at the Piper Jaffray 23rd Annual Healthcare Conference

CHARLOTTE, N.C., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Piper Jaffray 23rd Annual Healthcare Conference at 11:30 AM ET...
November 17, 2011 07:30 ET | Source: Chelsea Therapeutics

Chelsea Therapeutics Announces FDA Acceptance of NDA for Filing and Designation of Priority Review of NORTHERA(TM) for the Treatment of Symptomatic NOH

CHARLOTTE, N.C., Nov. 17, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right